Pere Mañé Takes the Helm as CEO of Suanfarma
Suanfarma, a prominent name in the development, production, and commercialization of active pharmaceutical ingredients (APIs), is excited to announce its new leadership change. Pere Mañé Godina has been appointed as the Chief Executive Officer (CEO) of the company, signaling a significant milestone for Suanfarma. The focus is now directed towards industrial consolidation, sustainable innovation, and ambitious global expansion.
Strengthening Leadership with Experience
Pere Mañé brings over 30 years of invaluable experience within the pharmaceutical industry. He has served in various technical and strategic executive roles at renowned companies like Uquifa, Boehringer Ingelheim, and Esteve Química. His career has seen a blend of technical, operational roles alongside executive capacities, including General Manager and Group Chief Industrial Operations Officer.
Transformative Impact at Esteve
His most recent role involved pivotal contributions to the industrial transformation at Esteve, marking its chemical division as a leader within the global market. Notably, during Pere’s tenure, Esteve received the esteemed accolade of CDMO of the Year – Small Molecules, awarded at the industry-renowned Leadership Awards.
Setting a Course for Growth
The appointment of Pere Mañé aligns seamlessly with the strategic vision of Suanfarma for future growth. Carlos Alonso, who presided as the interim CEO since the previous autumn, will assist in facilitating a smooth transition while continuing his journey within the company as Executive Chairman.
Expressing confidence in Pere’s capabilities, Carlos highlighted, "We believe that Pere’s extensive sector knowledge, strategic outlook, and proven leadership will be critical in fortifying Suanfarma’s market positioning while providing our clients and partners with high-value solutions."
Committed to Innovation and Excellence
Pere’s vision is reflective of a strong momentum aimed at propelling Suanfarma’s growth trajectory. He is prioritizing operational excellence and enhancing the company’s CDMO capabilities while fostering essential strategic partnerships. His approach will focus on:
- Streamlining operations and deploying new technologies
- Strengthening bonds with our global clients and critical suppliers
- Accelerating pathways toward international expansion
- Creating a culture centered on innovation and sustainability
In Pere’s words, "Suanfarma possesses every element necessary to spearhead the future of our industry: a solid base, an extraordinary industrial platform, and a comprehensive international network backed by a remarkable team. I am thrilled to embark on this new journey and collaborate to continually provide innovative, efficient, and sustainable solutions to our clientele."
About Suanfarma
Founded in 1993, Suanfarma serves as a B2B partner in the life sciences sector. The company remains dedicated to health and innovation through the sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients. With a presence that spans over 70 countries, Suanfarma has been under the umbrella of Archimed, a healthcare-focused investment firm, since 2021.
Frequently Asked Questions
Who is the new CEO of Suanfarma?
Pere Mañé Godina has been appointed as the new CEO of Suanfarma.
What are Pere Mañé's previous experiences?
Pere has over 30 years of experience in the pharmaceutical industry, holding roles at companies such as Uquifa and Boehringer Ingelheim.
What accolades did Esteve achieve under Pere's leadership?
During his tenure, Esteve was recognized as the CDMO of the Year – Small Molecules.
What is Suanfarma's mission?
Suanfarma aims to innovate in the health sector through sustainable development and high-quality pharmaceutical ingredients.
What strategic focuses will accompany Pere's leadership?
His leadership will prioritize operational excellence, strategic partnerships, and accelerating international growth.
